Core Viewpoint - eQ Plc has expanded its option program 2025 by 300,000 option rights, allowing for a total of 1,660,000 option rights, which can be converted into new shares, potentially increasing the company's share count by approximately 4% [1][2]. Group 1: Option Program Expansion - The Board of Directors has decided to expand the option program 2025, increasing the total number of option rights to 1,660,000 [1]. - The expansion allows holders to subscribe for up to 1,660,000 new shares, with a maximum dilutive effect of around 4% of the current shares [2]. Group 2: Employee Incentives - A total of 70,000 option rights will be granted to a key employee to encourage long-term shareholder value and align interests with the eQ Group [3]. - Approximately 25% of the eQ Group's personnel are participating in the option program 2025, indicating a significant employee engagement strategy [3]. Group 3: Company Overview - eQ is a Finnish group focused on asset management and corporate finance, managing approximately EUR 13.8 billion in assets [4]. - The company offers a range of services including mergers and acquisitions, real estate transactions, and equity capital markets through its subsidiary Advium Corporate Finance [4].

Core Points - The Annual General Meeting of Iceland Seafood International hf was held on 24 March 2026 [1] Group 1 - The results of the meeting were attached in a document [2]

Core Points - Air France-KLM filed its 2025 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on March 24, 2026 [1] - The document is available in French and can be accessed on both the AMF website and Air France-KLM's official website [2] - The Registration Document is published in European Single Electronic Format (ESEF) in XBRL and includes the Annual Financial Report, Board of Directors' report on corporate governance, Statutory Auditors' reports, and information on Statutory Auditors' fees [3] Investor Relations - Contact information for investor relations includes Michiel Klinkers and Marouane Mami, with their respective email addresses provided [4] - The official website for further information is www.airfranceklm.com [4]

Core Insights - LiveOne has announced a strategic B2B partnership with LG Electronics to expand its premium content ecosystem to millions of households in North America [1][2] Company Overview - LiveOne is a creator-first music, entertainment, and technology platform headquartered in Los Angeles, CA, offering premium experiences and content through memberships and live/virtual events [3] - The company operates several subsidiaries, including Slacker, PodcastOne, and LiveXLive, and is available on multiple platforms such as iOS, Android, Roku, and Apple TV [3] Strategic Partnership - The partnership with LG is aimed at scaling LiveOne's B2B distribution and enhancing its presence in the connected TV ecosystem [2] - This collaboration is expected to significantly expand LiveOne's addressable audience and improve engagement, advertising opportunities, and long-term monetization [2] Market Potential - The partnership targets the over $100 billion connected TV (CTV) market, where approximately 50% of consumers stream audio via smart TVs [5] - LG ships around 6 to 8 million TVs annually, and the U.S. CTV advertising spend is projected to reach $38 billion in 2026 [5] - LiveOne is expanding its B2B distribution network, which includes partnerships with major companies like Amazon, Apple, and YouTube [5]

Core Insights - Ipsos has appointed Alexandre Boissy as Deputy Chief Executive Officer, effective April 7, 2026, to enhance its global leadership and operational capabilities [2][5]. Group 1: Appointment Details - Alexandre Boissy will oversee Operations, the General Secretariat, Legal, Corporate Communications globally, and Investor Relations in coordination with the Finance Department [2]. - He will be a member of the Global Leadership Team (GLT) [2]. Group 2: Background of Alexandre Boissy - Boissy has over twenty years of executive experience within the Air France-KLM Group, most recently as Executive Vice-President Corporate Secretary [3]. - He has developed extensive expertise in corporate communication and institutional relations, working with various international stakeholders [3]. Group 3: Strategic Context - CEO Jean Laurent Poitou emphasized that Boissy's understanding of complex institutional environments and leadership during transformations will be crucial for executing the Horizons strategic plan [5]. - The Horizons plan aims to strengthen Ipsos' global leadership and accelerate its development [5]. Group 4: Boissy's Vision - Boissy expressed his honor in joining Ipsos during a pivotal time for the company and looks forward to enhancing global operations, governance, and institutional engagement [6]. Group 5: Company Overview - Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing nearly 20,000 people [7]. - The company offers 75 business solutions based on primary data from surveys, social media monitoring, and qualitative techniques [8].

Core Insights - Dogfish Head is launching a variety of seasonal beers and ready-to-drink cocktails for the spring and summer seasons, catering to diverse consumer preferences [1][3][4] Seasonal Beers - The lineup includes the return of two popular brews and a new variety pack, featuring light-bodied beers with refreshing flavors suitable for warmer weather [3] - Notable seasonal offerings include: - **Festina Pêche (4.5% ABV)**: A neo-Berliner Weiss brewed with real peaches, offering a blend of tangy and sweet notes, now available in 6pk/12oz cans [5] - **Aprihop (7.0% ABV)**: An American IPA with apricot puree, returning as part of the "Small Batch Series" in select Mid-Atlantic markets [5] - **Groovy Variety Pack**: A new 12pk/12oz can package featuring four off-centered ales, including Festina Pêche and other seasonal brews [5] Ready-to-Drink Cocktails - Dogfish Head's ready-to-drink cocktails combine house-made spirits with real fruit juices, providing bar-quality drinks in convenient packaging [4] - New offerings include: - **Blueberry Citrus Vodka Lemon Drop (7.0% ABV)**: A refreshing cocktail blending lemon and blueberry juices, now available in 4pk/12oz cans [4] - **Peach Mango Rum Punch (7.0% ABV)**: A fruit-forward cocktail made with real peach and mango juices [6] - Best-selling cocktails like **Strawberry Honeyberry Vodka Lemonade** and **Blood Orange Mango Vodka Crush** are now available in single-serve 570ml cans [6][7]

Group 1 - Ilkka Oyj acquired 1,352 shares at an average price of EUR 4.2240, totaling EUR 5,710.85 on 24 March 2026 [1] - After the acquisition, Ilkka Oyj holds a total of 134,261 treasury shares [1] Group 2 - Ilkka is a marketing and technology company that provides professional, data, and technology services in digital marketing and communications [2] - The core of Ilkka's business includes several key entities such as the software company Liana, the Swedish subsidiary Ungapped, and the data-driven sales and marketing expert Profinder [2] - The company focuses on utilizing modern technology, data, and AI to understand the entire purchase path, with an international focus on Sweden and emerging markets in the Middle East [2] - Ilkka employs approximately 330 marketing, technology, and data experts to deliver its services [2]

Core Viewpoint - VINCI SA has conducted share buybacks from March 16 to March 20, 2026, under the authorization from its General Meeting held on April 17, 2025, in compliance with regulations regarding share repurchases [2]. Group 1: Aggregate Presentation of Transactions - Total shares purchased during the specified period amounted to 132,587 shares, with an average purchase price of €126.66 [2]. - The daily breakdown of transactions shows varying volumes and average prices across different markets, with the highest daily volume recorded on March 20, 2026, at 33,659 shares [2]. Group 2: Daily Transactions Details - On March 16, 2026, VINCI purchased a total of 13,317 shares across multiple markets, with average prices ranging from €129.94 to €130.11 [2]. - On March 17, 2026, the company bought 14,481 shares, with average prices between €130.66 and €130.91 [2]. - On March 18, 2026, a total of 14,368 shares were acquired, with average prices from €129.42 to €129.74 [2]. - On March 19, 2026, VINCI purchased 14,678 shares, with average prices ranging from €126.29 to €126.41 [2]. - On March 20, 2026, the company bought 74,703 shares, with average prices between €124.44 and €124.79 [2].

Core Insights - Solvay has released its Annual Integrated Report for 2025, showcasing its financial, environmental, and societal performance [1][2] - The report highlights Solvay's achievements in advancing its strategic and sustainability commitments, enhancing competitiveness, and delivering sustainable solutions [3] Financial Performance - Solvay reported underlying net sales of €4.3 billion in 2025, reflecting its strong market position and operational resilience [6] Strategic and Sustainability Progress - The report illustrates how Solvay's Essential model and strategy have enabled the company to navigate a challenging environment while maintaining its commitment to sustainability [2][3] - It details the transformation of the company's culture, operating model, and governance, emphasizing the importance of sustainability in its operations [3] Availability of Information - The 2025 report, including the ESEF version, is accessible on Solvay's website in both English and French, along with a report on payments to governments [4]

Core Insights - Transgene is advancing its individualized neoantigen therapeutic vaccine, TG4050, which has shown durable clinical outcomes in head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapse [1][4][6] - The company has sufficient financial resources to support its operations until early 2028, following a successful fundraising of approximately €105 million and the conversion of €39 million debt into shares [21][26] - The randomized Phase 2 part of the clinical trial for TG4050 is nearing completion, with the primary endpoint being two-year disease-free survival [10][11] Clinical Development - TG4050 has demonstrated a 100% disease-free survival rate after more than two years of follow-up in the Phase 1 trial, meeting all trial endpoints [7][8] - A new Phase 1 trial for a second indication in operable solid tumors is planned to start in 2026, reflecting the strategy to expand the clinical evaluation of the myvac® platform [2][12] - Positive results from the Phase 1 trial of BT-001 support further clinical development, showing antitumoral activity in patients with advanced refractory tumors [15][17] Financial Performance - Operating revenue for 2025 was €7.2 million, an increase from €6.4 million in 2024, primarily driven by research tax credits [22][43] - The company reported a net loss of €37.5 million in 2025, compared to a net loss of €34.0 million in 2024, with a net cash burn of €38.2 million [26][48][50] - Cash, cash equivalents, and other financial assets totaled €111.9 million as of December 31, 2025, significantly up from €16.7 million at the end of 2024 [26][49] Strategic Initiatives - Transgene is optimizing its manufacturing processes to prepare for potential pivotal clinical trials [13] - The company is leveraging its proprietary VacDesignR® computational tool to enhance the quality and reliability of its vaccine production [14] - Recent leadership additions aim to accelerate the development of the myvac® platform, with new appointments in key executive roles [19][20]